Despite decades of progress in treating HIV, preventing new infections remains a critical global health challenge. Now, a new preventative medication, lenacapavir, offers a potential breakthrough with a less frequent dosing schedule than current options. Recently approved by both the European Medicines Agency and the U.S.Food and Drug Management for use as pre-exposure prophylaxis (PrEP), lenacapavir is administered via two injections per year, a significant shift from daily oral medication.
Since its discovery in the 1980s, the human immunodeficiency virus (HIV) has transformed from a feared diagnosis into a manageable condition thanks to decades of scientific progress. However, preventing new infections remains a significant challenge.
HIV is a particularly aggressive disease, directly attacking the immune system and gradually weakening the body’s defenses against other serious illnesses. Now, a new medication offers a promising preventative option: lenacapavir. This development is particularly important as rates of HIV infection continue to be a public health concern globally.
What is Lenacapavir and How Does it Prevent HIV?
Table of Contents
Lenacapavir represents a new generation of anti-HIV drugs. It’s a capsid inhibitor, targeting the structure that encases and protects the virus’s RNA along with the enzymes it needs to replicate.
Until recently, lenacapavir was used exclusively in individuals already infected with HIV, particularly those with resistance to other antiretroviral therapies. However, in recent months, both the European Medicines Agency and the U.S. Food and Drug Administration (FDA) approved its use as pre-exposure prophylaxis (PrEP) – a preventative treatment taken by individuals not infected with HIV to avoid contracting the virus.
This medication is indicated for those at higher risk of infection, such as sex workers or individuals with HIV-positive partners. PrEP has been available since 2019, but previously required a daily pill.
The approval of lenacapavir marks a milestone in the fight against HIV, as it’s the first preventative option that doesn’t rely on a daily dose. Instead, it offers a more practical regimen: two subcutaneous injections per year.
(Purificación León/EFE)
How Does Lenacapavir Work in HIV Prevention?
According to specialists at the Spanish National Research Council’s (CSIC) Institute of Medicinal Chemistry, lenacapavir directly binds to the HIV capsid, causing it to destabilize. This blocks the virus at two key moments:
- The transport of viral genetic material (RNA) into the human cell.
- The assembly and maturation of new viruses, preventing them from spreading.
The result is a double-action block that halts replication and limits the virus’s spread within the body. This characteristic makes it a highly effective drug, even against more resistant variants.
Why is a Two-Dose-a-Year HIV Treatment So Important?
Currently, traditional HIV treatment consists of a daily pill, and while effective, it faces common obstacles: missed doses, lack of access to healthcare facilities, or stigma associated with visible medication.
Lenacapavir addresses many of these issues. Infectious disease specialists highlight that a two-dose-a-year regimen can:
- Improve adherence by eliminating the need to take daily pills.
- Offer greater privacy, avoiding association of the medication with HIV.
- Facilitate use among young people and communities facing barriers to healthcare access.
- Ensure continuous protection, without interruptions due to missed doses.
(Purificación León/EFE)
HIV: A Complex Enemy
The human immunodeficiency virus is a retrovirus, meaning it uses RNA as its genetic material and requires copying it to DNA to integrate into human cells. Once inside, it infects CD4 lymphocytes, white blood cells that coordinate the immune response.
Over time, the destruction of these cells weakens the immune system, opening the door to serious infections and certain types of cancer. When this deterioration reaches a critical point, acquired immunodeficiency syndrome (AIDS) develops – the most severe form of HIV infection.
Fortunately, the expansion of antiretroviral therapy has drastically reduced the number of people developing AIDS. However, the infection persists, and preventing new infections remains crucial.
Lenacapavir: A Step Forward in the Global Strategy Against HIV
The World Health Organization (WHO) has already incorporated lenacapavir into its new guidelines and recommends its use twice a year for people at high risk.
According to its Director-General, Tedros Adhanom Ghebreyesus, this medication represents “a very good option” in a world where there is still no HIV vaccine.
With information from EFE.
